Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D-CAR T cells

被引：0
|
作者：
Hu, Xiaoli [1 ]
Zhou, Xinyi [1 ]
Zhao, Qian [2 ]
Yang, Ying [1 ]
Liang, Yang [3 ]
Xiao, Yuchen [4 ]
Liu, Zhuoqun [4 ]
Liu, Liu [5 ]
Zhang, Chao [6 ]
Du, Juan [1 ]
机构：
[1] Naval Med Univ, Shanghai Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China
[2] Univ Washington, Dept Mol Biol, Seattle, WA USA
[3] Sun Yat Sen Univ, Dept Hematol Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[4] Tongji Univ, Shanghai Yangzhi Rehabil Hosp, Fundamental Res Ctr, Shanghai Sunshine Rehabil Ctr,Sch Med, Shanghai, Peoples R China
[5] Shanghai Yuhui Pharmaceut Technol Grp Co Ltd, Shanghai, Peoples R China
[6] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Shanghai, Peoples R China
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 05期
基金：
中国国家自然科学基金;
关键词：
RECEPTOR;
D O I：
10.1111/bjh.19739
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2049 / 2052
页数：4
相关论文
共 50 条
  • [41] Bispecific T-Cell Engagers: Sequencing, BCMA, GPRC5D, and Resistance
    Krishnan, Amrita
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S98 - S99
  • [42] Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab
    Laheij, A. M. G. A.
    van de Donk, N. W. C. J.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
  • [43] Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells
    Mi, Xiaoli
    Penson, Alex
    Abdel-Wahab, Omar
    Mailankody, Sham
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (15): : 1435 - 1437
  • [44] Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells
    Mi, Xiaoli
    Penson, Alex
    Abdel-Wahab, Omar
    Mailankody, Sham
    BLOOD, 2023, 142
  • [45] Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).
    Huang, He
    Hu, Yongxian
    Zhang, Mingming
    Ding, Xiaomin
    Tang, Yu
    He, Xiaowen
    Chen, Siye
    Yang, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
    Xia, Jieyun
    Li, Zhenyu
    Xu, Kailin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [47] Sequential and persistent loss of BCMA and GPRC5D after bispecific antibodies in multiple myeloma revealed by whole genome sequencing
    Rasche, Leo
    Truger, Marietta
    Munawar, Umair
    Helal, Moutaz
    Han, Seungbin
    Zhou, Xiang
    Eisele, Florian
    Riedhammer, Christine
    Duell, Johannes
    Meggendorfer, Manja
    Mueller, Heiko
    Waldschmidt, Johannes
    Mersi, Julia
    Panther, Franziska
    Rosenwald, Andreas
    Haferlach, Claudia
    Einsele, Hermann
    Kortuem, Martin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S15 - S15
  • [48] Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)
    Lee, Holly
    Neri, Paola
    Ahn, Sungwoo
    Maity, Ranjan
    Leblay, Noemie
    Ziccheddu, Bachisio
    Chojnacka, Monika
    Tilmont, Remi
    Barakat, Elie
    Landgren, Ola
    Maura, Francesco
    Bahlis, Nizar Jacques
    BLOOD, 2022, 140
  • [49] Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma
    de Larrea, Carlos Fernandez
    Staehr, Mette
    Lopez, Andrea
    Chen, Yunxin
    Purdon, Terence J.
    Ng, Khong Y.
    Wendel, Hans
    Brentjens, Renier J.
    Smith, Eric L.
    BLOOD, 2019, 134
  • [50] Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
    Jieyun Xia
    Zhenyu Li
    Kailin Xu
    Journal of Hematology & Oncology, 16
12345